IOVA
Iovance Biotherapeutics, Inc. NASDAQ Listed Oct 15, 2010$3.55
Mkt Cap $1.3B
52w Low $1.64
47.9% of range
52w High $5.63
50d MA $3.81
200d MA $2.78
P/E (TTM)
-3.1x
EV/EBITDA
-2.4x
P/B
1.7x
Debt/Equity
0.1x
ROE
-56.0%
P/FCF
-2.9x
RSI (14)
—
ATR (14)
—
Beta
0.76
50d MA
$3.81
200d MA
$2.78
Avg Volume
15.7M
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
825 Industrial Road · San Carlos, CA 94070 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 4.09 | -14.2% | -13.2% | — | — | — | — | — |
| Feb 24, 2026 | AMC | -0.22 | -0.18 | +18.2% | 3.78 | +10.3% | +1.3% | -1.0% | +1.8% | -1.8% | -1.1% | — |
| Nov 6, 2025 | AMC | -0.29 | -0.25 | +13.8% | 2.31 | -2.6% | -0.4% | +3.0% | +11.8% | -4.2% | -5.1% | — |
| Aug 7, 2025 | AMC | -0.29 | -0.33 | -13.8% | 2.64 | -27.7% | -20.1% | -6.6% | +13.2% | +9.9% | +0.0% | — |
| May 8, 2025 | AMC | -0.25 | -0.36 | -44.0% | 3.17 | -38.8% | -44.8% | +10.3% | -7.3% | -4.5% | +2.9% | — |
| Feb 27, 2025 | AMC | -0.26 | -0.26 | +0.0% | 5.26 | -25.3% | -19.4% | -4.7% | -3.0% | +3.3% | -7.4% | — |
| Nov 7, 2024 | AMC | -0.31 | -0.28 | +9.7% | 12.28 | -13.1% | -13.8% | +0.6% | -9.0% | -7.1% | -4.6% | — |
| Aug 8, 2024 | AMC | -0.37 | -0.34 | +8.1% | 7.94 | +18.3% | +24.9% | +1.7% | +6.4% | -5.9% | +5.5% | — |
| May 9, 2024 | AMC | -0.45 | -0.42 | +6.7% | 13.45 | -3.0% | -18.4% | -0.8% | -1.5% | -0.4% | -2.3% | — |
| Feb 28, 2024 | AMC | -0.44 | -0.45 | -2.3% | 17.43 | -3.4% | -8.7% | +5.5% | +1.0% | -2.8% | +4.1% | — |
| Nov 7, 2023 | AMC | -0.46 | -0.46 | +0.0% | 4.32 | +3.9% | -3.5% | -5.3% | +0.5% | +1.5% | +16.9% | — |
| Aug 8, 2023 | AMC | -0.81 | -0.47 | +42.0% | 7.14 | -0.7% | +6.4% | -5.4% | -1.8% | +0.8% | +5.5% | — |
| May 9, 2023 | AMC | -0.84 | -0.50 | +40.5% | 7.36 | +3.5% | +3.8% | -1.8% | -0.4% | +5.0% | -4.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 10 | Chardan Capital | Maintains | Buy → Buy | — | $4.01 | $3.99 | -0.5% | -7.7% | -6.5% | +5.2% | +4.9% | -0.5% |
| Mar 5 | UBS | Maintains | Neutral → Neutral | — | $4.26 | $4.21 | -1.2% | +7.5% | +12.0% | +5.5% | -3.9% | -6.9% |
| Mar 3 | Citizens | Upgrade | Market Perform → Market Outperform | — | $3.79 | $3.62 | -4.5% | -1.1% | +13.6% | +7.5% | +12.0% | +5.5% |
| Feb 25 | Citizens | Upgrade | Market Perform → Market Outperform | — | $3.78 | $4.17 | +10.3% | +1.3% | -1.0% | +1.8% | -1.8% | -1.1% |
| Feb 25 | Barclays | Maintains | Overweight → Overweight | — | $3.78 | $4.17 | +10.3% | +1.3% | -1.0% | +1.8% | -1.8% | -1.1% |
| Dec 17 | Barclays | Maintains | Overweight → Overweight | — | $2.25 | $2.26 | +0.4% | +12.0% | -2.4% | +0.8% | +12.1% | +1.4% |
| Nov 24 | Barclays | Maintains | Overweight → Overweight | — | $2.24 | $2.28 | +1.8% | +11.6% | -0.8% | -1.6% | +1.2% | -9.7% |
| Nov 6 | Chardan Capital | Maintains | Buy → Buy | — | $1.81 | $2.26 | +24.9% | +27.6% | -0.4% | +3.0% | +11.8% | -4.2% |
| Oct 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.19 | $2.16 | -1.4% | -8.7% | -2.5% | +1.0% | -1.0% | -6.7% |
| Aug 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.50 | $2.81 | +12.4% | +4.0% | -2.7% | +0.4% | +5.9% | -5.9% |
| Aug 8 | Wells Fargo | Maintains | Overweight → Overweight | — | $2.64 | $1.91 | -27.7% | -20.1% | -6.6% | +13.2% | +9.9% | +0.0% |
| Aug 8 | Chardan Capital | Maintains | Buy → Buy | — | $2.64 | $1.91 | -27.7% | -20.1% | -6.6% | +13.2% | +9.9% | +0.0% |
| Jul 23 | Chardan Capital | Maintains | Buy → Buy | — | $3.13 | $3.75 | +19.8% | +26.8% | -17.1% | -4.9% | -5.8% | -1.0% |
| May 16 | UBS | Downgrade | Buy → Neutral | — | $1.76 | $1.70 | -3.4% | -5.7% | +10.2% | +4.4% | -7.9% | -0.6% |
| May 12 | Goldman Sachs | Maintains | Buy → Buy | — | $1.75 | $1.85 | +5.7% | +10.3% | -7.3% | -4.5% | +2.9% | -5.7% |
| May 12 | Mizuho | Maintains | Outperform → Outperform | — | $1.75 | $1.85 | +5.7% | +10.3% | -7.3% | -4.5% | +2.9% | -5.7% |
| May 12 | Barclays | Maintains | Overweight → Overweight | — | $1.75 | $1.85 | +5.7% | +10.3% | -7.3% | -4.5% | +2.9% | -5.7% |
| May 9 | JMP Securities | Downgrade | Market Outperform → Market Perform | — | $3.17 | $1.94 | -38.8% | -44.8% | +10.3% | -7.3% | -4.5% | +2.9% |
| May 9 | Chardan Capital | Maintains | Buy → Buy | — | $3.17 | $1.94 | -38.8% | -44.8% | +10.3% | -7.3% | -4.5% | +2.9% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.17 | $1.94 | -38.8% | -44.8% | +10.3% | -7.3% | -4.5% | +2.9% |
| Apr 17 | Goldman Sachs | Maintains | Buy → Buy | — | $3.07 | $3.05 | -0.7% | -0.3% | +0.7% | +4.2% | -0.6% | +5.3% |
| Apr 14 | Barclays | Maintains | Overweight → Overweight | — | $3.30 | $3.37 | +2.1% | +3.3% | -5.3% | -5.0% | -0.3% | +0.7% |
| Mar 3 | Goldman Sachs | Maintains | Buy → Buy | — | $4.24 | $4.27 | +0.7% | -4.7% | -3.0% | +3.3% | -7.4% | +0.0% |
| Mar 3 | Truist | Maintains | Buy → Buy | — | $4.24 | $4.27 | +0.7% | -4.7% | -3.0% | +3.3% | -7.4% | +0.0% |
| Mar 3 | Chardan Capital | Maintains | Buy → Buy | — | $4.24 | $4.27 | +0.7% | -4.7% | -3.0% | +3.3% | -7.4% | +0.0% |
| Feb 28 | Baird | Maintains | Outperform → Outperform | — | $5.26 | $3.93 | -25.3% | -19.4% | -4.7% | -3.0% | +3.3% | -7.4% |
| Feb 28 | Piper Sandler | Maintains | Neutral → Neutral | — | $5.26 | $3.93 | -25.3% | -19.4% | -4.7% | -3.0% | +3.3% | -7.4% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.26 | $3.93 | -25.3% | -19.4% | -4.7% | -3.0% | +3.3% | -7.4% |
| Jan 31 | Piper Sandler | Maintains | Neutral → Neutral | — | $6.21 | $6.12 | -1.4% | -5.8% | -3.6% | +3.0% | +5.0% | -3.6% |
| Nov 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.66 | $12.09 | +3.7% | +4.1% | +1.2% | -13.8% | +0.6% | -9.0% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.92 | $9.97 | +0.5% | +1.7% | +6.4% | -5.9% | +5.5% | -1.6% |
| Jul 29 | Piper Sandler | Downgrade | Overweight → Neutral | — | $9.25 | $8.43 | -8.9% | -2.2% | -1.0% | -2.6% | -6.5% | -4.5% |
| Jun 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.01 | $8.05 | +0.5% | +0.1% | +0.5% | -4.1% | -4.4% | -1.5% |
| Jun 20 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $8.00 | $7.82 | -2.2% | -0.4% | +0.5% | +1.9% | +3.6% | -4.0% |
| Jun 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.88 | $8.87 | -0.1% | -5.7% | -3.2% | +2.7% | -2.2% | -4.4% |
| May 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.00 | $8.99 | -0.1% | -1.3% | -5.7% | -3.2% | +2.7% | -2.2% |
| May 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.26 | $10.87 | +5.9% | -2.4% | -3.1% | -4.3% | -3.0% | -1.3% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.45 | $13.04 | -3.0% | -18.4% | -0.8% | -1.5% | -0.4% | -2.3% |
| Mar 14 | Piper Sandler | Maintains | Overweight → Overweight | — | $14.73 | $14.70 | -0.2% | -3.5% | -2.1% | +0.9% | -0.9% | +7.4% |
| Mar 7 | Truist | Maintains | Buy → Buy | — | $17.16 | $17.40 | +1.4% | -3.1% | -5.5% | -3.8% | -2.5% | +0.1% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.79 | $18.10 | +7.8% | +1.0% | -2.8% | +4.1% | -3.1% | -5.5% |
| Mar 1 | Wells Fargo | Maintains | Overweight → Overweight | — | $15.91 | $16.36 | +2.8% | +5.5% | +1.0% | -2.8% | +4.1% | -3.1% |
| Feb 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.43 | $16.83 | -3.4% | -8.7% | +5.5% | +1.0% | -2.8% | +4.1% |
| Feb 29 | Barclays | Maintains | Overweight → Overweight | — | $17.43 | $16.83 | -3.4% | -8.7% | +5.5% | +1.0% | -2.8% | +4.1% |
| Feb 29 | Goldman Sachs | Maintains | Buy → Buy | — | $17.43 | $16.83 | -3.4% | -8.7% | +5.5% | +1.0% | -2.8% | +4.1% |
| Feb 21 | Goldman Sachs | Maintains | Buy → Buy | — | $12.03 | $12.10 | +0.6% | +31.1% | +1.1% | -1.1% | +5.3% | +5.2% |
| Feb 20 | Goldman Sachs | Maintains | Buy → Buy | — | $9.15 | $11.65 | +27.3% | +31.5% | +31.1% | +1.1% | -1.1% | +5.3% |
| Feb 20 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $9.15 | $11.65 | +27.3% | +31.5% | +31.1% | +1.1% | -1.1% | +5.3% |
| Feb 20 | Chardan Capital | Maintains | Buy → Buy | — | $9.15 | $11.65 | +27.3% | +31.5% | +31.1% | +1.1% | -1.1% | +5.3% |
| Feb 20 | Piper Sandler | Maintains | Overweight → Overweight | — | $9.15 | $11.65 | +27.3% | +31.5% | +31.1% | +1.1% | -1.1% | +5.3% |
No insider trades available.
8-K · 2.02
!! High
Iovance Biotherapeutics, Inc. -- 8-K 2.02: Earnings Results
Iovance Biotherapeutics reported financial results and operational updates via press release, though the specific performance metrics and guidance changes require reviewing the full disclosure for investor impact assessment.
May 7
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Inovio's executive departure suggests potential leadership instability that could delay clinical programs or vaccine commercialization efforts, creating near-term uncertainty for investors betting on the company's pipeline success.
Mar 20
8-K · 8.01
!! High
Iovance Biotherapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Iovance Biotherapeutics updated its corporate presentation materials for healthcare conferences and investor meetings, signaling potential strategic updates or progress in its pipeline that management wants to communicate to investors.
Feb 24
Data updated apr 25, 2026 4:01pm
· Source: massive.com